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Abstract: Background: This literature review investigates the economic costs of childhood disability
analysing methodologies used and summarizing the burden worldwide comparing developed and
developing countries. Methods: Four electronic databases were searched. Studies were categorised
according to country, perspective, methods of costing, disability category, and time horizon. Annual
costs were converted to 2019 current US dollars then compared to the country’s per capita current
health expenditure (CHE) and gross domestic product (GDP). Results: Of 2468 references identi-
fied, 20 were included in the review. Annual burden of childhood disability ranged ≈$450–69,500
worldwide. Childhood disability imposes a heavy economic burden on families, health systems,
and societies. The reason for the wide range of costs is the variability in perspective, costs included,
methods, and disability type. Conclusion: The annual societal costs for one disabled child could be
up to the country’s GDP per capita. The burden is heavier on households in developing countries
as most of the costs are paid out-of-pocket leading to impoverishment of the whole family. Efforts
should be directed to avoid preventable childhood disabilities and to support disabled children and
their households to make them more independent and increase their productivity. More studies from
developing countries are needed.
Keywords: child; disability; burden; cost
1. Introduction
Around one billion (15% of the world population) have some level of disability ac-
cording to the World Health Organization (WHO) and World Bank [1,2]. There is currently
no reliable estimate for the number of disabled children around the world [3,4]; however,
estimates vary between 0.4–12.7% [5]. This is partly due to differences in defining disability.
The more accepted approach in defining disability is the “bio-psycho-social model” which
defines disability not only based on the individual’s health condition, but rather the inter-
action between the health condition and contextual factors (environmental/personal) [1].
Research shows an association between poverty and disability [6–9] but the relation-
ship is complex and moves in both directions. A disabled child has less access to schooling
and lower probability of continuing to higher education which means less human capi-
tal accumulation leading to unemployment or lower paid jobs and inevitably leading to
chronic poverty [1,10–12]. Childhood disability can also impoverish the household because
of direct extra costs of caring for the disabled child (e.g., healthcare, wheelchair, child care)
and indirect costs (e.g., job loss to care for the child or having to work part-time/ flexible
hours) [6,13–17]. On the other hand, poverty is a risk factor for childhood disability. Poor
nutrition and water sanitation, unsafe antenatal care, and high prevalence of preventable
diseases and accidents among less advantaged individuals increases the risk of childhood
and adult disability especially in developing countries [3,13]. There is also a big dispar-
ity between evidence arising from developed versus developing countries regarding the
association between poverty and disability [1,3,6,10].
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Cost of illness studies have been published since the late 1950s. Reference [18] in 1967,
Dorothy Rice, proposed a model for cost of illness that differentiates direct and indirect
costs [19]. The choice of what costs to include, in the present and in the future, is subject
to debate [20]. The perspective of the costing study (patient/household, health system,
or society) plays an important role in what costs to include or exclude from the analysis.
Recent efforts have been made to provide guidelines for healthcare costing studies. The
most notable is the “Reference Case for Estimating the Costs of Global Health Services
and Interventions” by the Global Health Cost Consortium (GHCC) launched in 2016. The
reference case aims at improving consistency and transparency of methods, assumptions,
and reporting [21].
Previous reviews discussed the costs of disability in children [22–24] but none could
calculate figures due to lack of consistency in methods for defining disability and esti-
mation of costs. To the best of our knowledge, no reviews have compared developed vs.
developing countries.
This research intends to be the first to study the costs of childhood disabilities compar-
ing country, perspective, methods of costing, disability category, and time horizon. Beside
reporting costs, we analyse the methodologies used in different studies for calculating cost
of illness and their relevance to the setting and perspective. We also compared annual
costs to the current health expenditure per capita and to the GDP per capita to show the
magnitude of the burden.
The aim of this work is to investigate the costs of childhood disability in developed
and developing countries through a literature review. The objectives are:
1. To identify costs of childhood disability from selected references and categorize them
according to setting, type of disability, perspective, and time horizon.
2. To quantify the burden of disability on the health system and society by comparing
the cost to current health expenditure (CHE) per capita and gross domestic product
(GDP) per capita.
To provide critical qualitative comparison between developed and developing countries.
2. Materials and Methods
A literature review was conducted largely following Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA) guidelines [25,26]. Only one researcher
performed the initial search, selection of articles, and critical appraisal (AS). All previous
steps were then revised, corrected, and approved by the second researcher (GG). However,
the two researchers did not perform the evaluation independently hence it is considered a
literature review not a systematic review.
Literature was searched for the key terms of cost, child, and disability. Alternative
search terms were also used for each key word. Selecting the search terms for disability
was challenging as there is a wide range of medical conditions which may cause disability.
In this review, we used keywords general to the concept of disability. In addition, we
searched for three of the most common medical conditions causing childhood disability;
cerebral palsy (CP), autism spectrum disorders (ASD), and Down syndrome (DS). These
medical conditions were selected because they almost always occur/manifest in childhood,
cause considerable disability, and have long survival so the costs can be followed for a
longer time.
Inclusion criteria were: peer reviewed journal articles, from 1980 onwards, in the
English language only, estimating any type of economic costs of children (up to the age of
18), with any type of disability.
Countries were categorised as developed or developing. All high-income countries
were considered “developed”, all low-and-middle-income countries (LMIC) were consid-
ered “developing”. Ranking of countries’ income levels was taken from the latest World
Bank country and lending group ranking [27].
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2.1. Searching Strategy and Databases
The databases Medline, Embase, EconLit, and Global Health were searched. Alter-
native search strategies were also used through snowball sampling [28] where the search
strategy evolves based on the relevant literature identified through the initial electronic
search. This included searching reference lists, hand searching relevant journals and
author searching. Details of the search strategies on the four databases is available in
Appendices A–D.
2.2. Identifying Relevant Literature
The searching and sifting process was performed largely following PRISMA guide-
lines [26]. The results of electronic database searches were uploaded and managed using
Mendeley reference management software and duplicates were removed. Titles were
screened against inclusion criteria. After exclusion of irrelevant titles, abstracts of the
remaining references were screened again. The full text of the remaining references was
retrieved, and critical appraisal of their quality was performed. At this stage, more full
text articles were included through snowball sampling while some studies were excluded
because full text could not be found.
2.3. Data Extraction
A data extraction form was designed using google-docs. The form had two sections,
one for data extraction and another for the critical appraisal questions. Data were then
exported into an excel file for analysis. The form can be viewed at https://forms.gle/
ntoEivcgT5xN7Agd9 (accessed on 13 July 2019).
2.4. Categorizing Costs
Types of costs were categorised into the following:
• Direct-medical: costs for diagnosis, treatment, managing complications of the condi-
tion causing the disability.
• Direct non-medical: includes special education, rehabilitation, and transportation costs.
• Indirect non-medical: productivity loss and time lost by parents due to caring for the
disabled child.
• Future related: medical costs related to the condition causing disability that happen in
the future years.
• Future unrelated: includes future productivity loss by the disabled children and
their caregivers.
2.5. Critical Appraisal
A modification of the 10-point checklist by Drummond et al. [29] was used to evaluate
the quality of the articles. The checklist was originally designed to critically appraise eco-
nomic evaluation studies, hence rephrasing and excluding some questions was necessary.
The modified checklist contained 20 yes/no questions. All questions were given equal
weight. Studies scoring yes in more than 75% of the applicable questions were considered
to have a low risk of bias, whereas, those scoring (50–75%) a moderate risk of bias, and
studies scoring less than 50% a high risk of bias.
When an item is partially met it was considered (yes). However, all items were
reviewed again by the second researcher (GG) and discussed to reach a final decision
on assigning the question a yes/no answer. The critical appraisal tool is available in
Appendix E.
2.6. Synthesis of Evidence
Qualitative comparison was made between studies by categorising and analysing
them according to the following items:
# Country (name, developed/developing)
# Perspective (household, health system, or societal perspective)
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# Methods of costing
# Disability category (types of disability/medical condition)
# Time horizon
The data extraction table is available in Appendix F.
For quantitative comparison, annual costs reported in the studies were compared
to the CHE per capita of the country obtained from the latest estimates published by the
WHO in 2016 [30] and then the figures were inflated to 2019 US$. Comparison was also
made with GDP per capita for the country obtained from the International Monetary Fund
(IMF) projections for GDP published in the World Economic Outlook Database in April
2019 [31]. Lifetime costs were transformed to annual costs by dividing the lifetime costs by
the number of years reported in the study model. The ratios of the annual costs to CHE
and GDP were displayed as percentages in the results table. The ratios were displayed in
a scatterplot after they were transformed to natural logs to minimize the scale and make
it easier for display. This means that the midline (zero) corresponds to 100%, i.e., the
estimated cost is equal to the CHE/GDP per capita. All the data point to the right of the
midline (positive) are multiples of the CHE/GDP per capita i.e., the costs are more than
CHE/GDP per capita. Any data points to the left of the midline (negative) are fractions
of the CHE/GDP per capita i.e., the costs are less than the CHE/GDP per capita. The
studies were arranged chronologically from oldest (bottom) to newest (top) to show if
there was a trend over time. A different colour was given to data points for each of the
three perspectives (the household, the health system, and the societal). A different shape
was given to data points to differentiate annual costs reported in the original studies from
annual costs that we estimated from the lifetime costs. As some studies estimated separate
costs for more than one type of disability, each data point on the scatter plot represents a
cost estimate rather than a study.
2.7. Summarizing Results and Currency Conversion
For comparability, all results were displayed in 2019 US dollars (US$). Costs from
the original studies were first inflated to 2019 local currency values using local currency
inflation rate from consumer price index of the international monetary fund [32]. Costs in
currencies other than US$ were then converted to 2019 US$ using the exchange rate of the
base year (July 2019 conversion rate).
Costs were reported as average (mean) cost whenever possible. If both mean and
median are reported; the mean was chosen. Because the 95% confidence interval was not
available in all studies, it was not reported in our results. Costs were rounded and presented
as approximate figures (≈) to emphasize the idea that these costs need to be compared
categorically rather than statistically. However, the actual (non-rounded) estimates are
presented in the results table.
3. Results
3.1. Finding Relevant Studies
The initial literature search identified 2468 references. After removal of 517 duplicates,
the titles of the remaining 1951 references were screened. Of these, 251 were retained for
abstract review applying the inclusion and exclusion criteria. After revising the abstracts,
53 references were selected for full text review and a further three were found through
snowball sampling. The critical appraisal tool was applied to 34 studies, 17 were found to
have low risk of bias and were, therefore, included in this review. Only two studies from
this group were from a developing country. Fourteen studies had moderate risk of bias and
were, therefore, excluded. We exceptionally included three studies from the moderate risk
of bias group as they were from developing countries, so they were needed for the sake
of comparison. All studies with high risk of bias were excluded (n = 3). This resulted in
20 studies that were included in the final analysis. Details of the sifting process are shown
in Figure 1.
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Figure 1. Literature selection process.
3.2. Summary of the Results
The annual costs of childhood disability reported in the studies ranged ≈$450–69,500.
In developing countries, the costs ranged ≈$500–7500 while in developed countries it
ranged ≈$450–69,500.
The lifetime costs ranged ≈$41,000–4,300,00 worldwide. In developing countries, costs
ranged ≈$41,000–91,000 while in developed countries the range was ≈$32,000–4,300,000.
The 20 studies were spread across 12 countries in five continents. The majority (n = 15)
were set in developed countries. Figure 2 shows the distribution of the reviewed studies
over the world map.
Regarding type of disability; six studies estimated the costs of disability in general
or reported the costs of more than one category of disability. Six studies focused on the
costs of autism spectrum disorders (ASD), four on cerebral palsy (CP), and three on Down
syndrome (DS). Only one study estimated the costs of disability as a sequel of meningitis.
Regarding study perspective; the societal perspective was considered in 10 studies, the
household perspective in six, while four studies were from the health system perspective.
Regarding time horizon; more than half of the studies (n = 12) reported the annual
costs, whereas six estimated the lifetime costs. The study by Solmi et al. [33] was the
only one to report weekly extra costs. Barrett et al. [34] reported costs over a six-month
period. Kageleiry et al. [35] presented the aggregate costs for the whole childhood period
(0–18 years) which was difficult to break down into annual costs but could, nevertheless,
be compared to lifetime costs regarding the methodology.
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A summary of the findings from the 21 studies is presented in Table 1.
General Methodological Findings
The definition of disability varied between the reviewed studies. The majority of the
studies (n = 14) identified disabled children based on a confirmed diagnosis of a medical
condition, whereas only three studies used a definition that follows the bio-psycho-social
model. Thre studies were not clear on th method of defining disability.
The persp ctive of the analysis was determi ant in the choice of study methods a d
the types of cost included. Th soci tal perspective was more commonly used in developed
countries. Nine out of 15 of the stu ies from developed countries focused on the societal
perspective, five were from the health system perspective and only one was from the
household perspective. In fact, seven out of eight studies from European Union (EU)
countries were from a societal perspective. In developing countries, four out of five studies
were from the household perspective, only one from the societal perspective and none
from the health system perspective.
The most frequently measured costs were direct medical and direct non-medical costs
which were estimated in 17 and 16 studies, respectively. Indirect non-medical costs were
estimated in 11 studies, future-related (medical) costs in six, and future unrelated costs in
only five studies.
Whenever the method of estimating indirect non-medical costs is explicitly mentioned
it was the human capital approach. The only exception in developed countries was
the novel use of compensating variation method by Solmi et al. [33] The friction cost
method was not used in any of the reviewed studies and was not found in any of the
34 studies included in the critical appraisal. Two studies from developing countries
estimated productivity loss by directly asking parents on their estimation of income forgone
rather than the standard estimation through the human capital approach method [36,37].
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Table 1. Results of the literature review on costs of childhood disability.
First Author and








2019 US$ (% of
Estimated Costs) *
GDP per Capita
2019 US$ (% of
Estimated Costs) **
Solmi [33], 2018 UK, Developed Household Weekly
Mentally
Disabled Annual 3625 4267 (85%) 42,310 (9%)
Severely
Disabled Annual 4200 4267 (98%) 42,310 (10%)
Physically
Disabled Annual 2600 4267 (61%) 42,310 (6%)
Knapp [38], 2009 UK, Developed Societal Lifetime ASD
Lifetime 2,060,060
Annual † 42,539 4267 (997%) 42,310 (101%)
Ganz [39], 2007 USA, Developed Societal Lifetime ASD
Lifetime 4,345,600
Annual 69,530 10,640 (653%) 64,767 (107%)
Wilson [43], 2005 USA, Developed Societal Annual
Chronically
ill Annual 36,310 10,640 (341%) 64,767 (56%)
HIV
positive Annual 13,039 10,640 (123%) 64,767 (20%)













Jarbrink [44], 2007 Sweden, Developed Societal Annual ASD Annual 68,863 6156 (1119%) 53,004 (130%)
Geelhoed [45], 2011 Australia, Developed Health system Annual DS Annual 3602 5393 (67%) 55,421 (6%)
Roddy [46], 2019 Ireland, Developed Societal Annual ASD Annual 49,867 5130 (972%) 76,911 (65%)
Wang [42], 2008 China, Developing Societal Lifetime CP
Lifetime 91,046
Annual 2365 429 (551%) 10,153 (23%)
Genereaux [47], 2015 Canada, Developed Societal Annual IDD Annual 60,059 4806 (1250%) 46,419 (129%)
Martınez-Valverde
[48], 2019 Mexico, Developing Household Annual DS Annual 501 498 (101%) 9858 (5%)
Newacheck [49],
2004 USA, Developed Health system Annual Multiple Annual 3833 10,640 (36%) 64,767 (6%)
Hoving [50], 2007 Netherlands,Developed Societal Annual CP Annual 57,383 5112 (1123%) 53,016 (108%)
Kageleiry [35], 2016 USA, Developed Health system Childhood(0–18 yrs) DS
0–18 yrs 275,603
Annual 15,311 10,640 (144%) 64,767 (24%)
Park [41], 2011
South Korea,
Developed Health system Lifetime CP
Lifetime 32,003
Annual 457 2203 (21%) 30,028 (1%)
Barrett [34], 2015 UK, Developed societal 6 months
Autistic




Annual 29,503 4267 (691%) 42,310 (70%)
ASD Annual 28,548 4267 (669%) 42,310 (67%)
Peng [51], 2009 USA, Developed Health system Annual PDD Annual 10,538 10,640 (99%) 64,767 (16%)




Annual 1374 58 (2370%) 1510 (91%)
Xiong [52], 2011 China, Developing Household Annual
Autism Annual 3566 429 (831%) 10,153 (35%)
Physical
Disability Annual 2989 429 (697%) 10,153 (29%)
Mental
Disability Annual 1164 429 (271%) 10,153 (11%)
Ou [37], 2015 China, Developing Household Annual ASD Annual 7470 429 (1741%) 10,153 (74%)
* % = (annual costs/current health expenditure (CHE) per capita). ** % = (annual costs/gross domestic product (GDP) per capita). Studies
are arranged by strength of evidence according to our critical appraisal tool, the highest quality at the top. ASD = Autism Spectrum
Disorders, CP = Cerebral Palsy, DS = Down Syndrome, IDD = Intellectual Developmental Disorder, PDD = Pervasive Developmental
Disorder. Care must be taken not to simply compare the costs from different studies as there are considerable methodological differences
between them, this table is just a way of summarizing these differences. † The study by Knapp et al estimated both annual costs (survey
based) and modelled lifetime costs (model based). Unlike the rest of lifetime studies in this review, what we are presenting for this study as
annual cost is the number reported by Knapp not our calculation from dividing lifetime costs by number of years in the model.
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3.3. Lifetime Cost Studies
The lifetime costs ranged ≈$41,000–4,300,00 this corresponds to annual costs of
≈$450–69,500. Six studies estimated lifetime costs of disability. These studies were in-
cluded even though cost estimation continued into adulthood because it is a long-term
consequence of disability acquired at birth or during childhood. Four of the studies were
from the societal perspective, one from the health system perspective, and one from the
household perspective.
The method of estimation of lifetime costs was similar in the six studies; the inci-
dence/prevalence of the condition is estimated, then average costs at each age band till
the end of life expectancy is estimated. This estimate is then used to model the lifetime
costs for a hypothetical person (or cohort) who acquires the condition at the base year and
dies at the end of life expectancy. Therefore, we considered lifetime costs studies to be
model-based studies to differentiate them from other studies which estimate annual costs
in real-time in the current year(s) i.e., survey-based.
Discounting was used for future costs (ranging 3–5%) in all the lifetime studies.
Sensitivity analysis to account for uncertainty around the measures estimated in the study
was used in five of the six studies.
The study by Griffiths et al. [36] on lifetime costs of meningitis sequelae in children in
Senegal was the only one from a developing country and was the only study to be truncated
at the age of 30 years, while the remaining five studies were from developed countries and
truncated at an age not far from the average life expectancy of the population.
The six studies focused on a single disease or a group of very similar disorders; three
on CP, two on ASD, and one on meningitis sequelae. Regarding data sources, two studies
pooled data from different studies to estimate the average costs, [38,39] two used national
register data, [40,41] and two estimated costs based on parents’ reported expenditures and
healthcare utilization [36,42].
3.4. Magnitude of the Burden
It was not possible to compare the studies quantitatively because of methodological
differences. However, we attempted to estimate the ratios of annual costs to their country’s
own per capita CHE and GPD and display it graphically in a scatter plot. This plot would
allow the reader to visualise results in a comparable way and show the general differences
between countries and between perspectives. On the scatterplot, annual costs estimated
through survey-based methods were given a different shape (triangle) to differentiate them
from annual costs that we estimated from the reported lifetime costs studies model-based
method (circle).
Figure 3 is a scatterplot that shows the ratio of each estimated cost to the country’s
CHE per capita. All the costs estimated from the societal perspective (yellow) were to the
right of the midline, i.e., higher than CHE per capita. From the household perspective (red),
costs estimated in China and Senegal were higher than CHE per capita, costs from Mexico
were equal to CHE per capita, and costs from the UK were equal or less than CHE per
capita. From the health system perspective (green), costs were generally lower compared
to the other perspectives. Costs estimated in Korea and Australia were lower than CHE
per capita. Three cost estimates from the USA in the years 2004, 2011, and 2016 were lower
than, equal, and higher than the CHE per capita respectively. This may indicate a trend of
rising healthcare costs in the USA; however, type of disability and methods could be major
confounding factors.
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Figure 4. Annual childhood disability costs compared with GDP per capita. Care must be taken not to simply compare the
costs from different studies as there are considerable methodological differences between them, this graph is just a way of
summarizing these differences.
. i i
ll reviewed studies concluded that there is a substantial economic burden attributed
to childhood disability regardless of the study perspective or setting. The household of the
disabled child bears a heavy economic burden. This is either in the form of out-of-pocket
(OOP) expenditures, or opportunity costs due to productivity time lost caring for the
disabled child. This is true even in countries with public coverage of health, education, and
social services. This economic burden is shared by the family of the disabled child, public
health services, and the society. The share of each party is variable depending on the health
and welfare system in the study setting. In developing countries, much of the burden
is on the household in the form of OOP expenditures and lost productivity. In Mexico,
Martınez-Valverde et al. found that 33% of families with DS children had catastrophic
expenses and 46% of the families had to borrow money to pay for medical expenses [48].
In developed countri , part of the burden is shifted to the public services (e.g., health,
special education, and disability benefits) but there is still a substantial burden on the
families. In the UK, an additional annual amo nt of ≈$4200 is needed for the families of a
severely disabled child to h ve the same living standard of their matched families without
a disabled child [33,53].
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4.1. Definition of Disability
The WHO report on disability recommended the bio-psycho-social model for defining
disability as an interaction between the physical condition and the environment [1]. This
was only used in three of the 20 reviewed studies while the majority used confirmed clinical
diagnosis of a certain disease as the indication of disability. However, this may be biased
because the literature search was done in databases which focus primarily on medical
rather than social research.
The definition of disability varies globally, even within some countries there is no
consensus on the national definition which explains why different studies produce different
prevalence rates for the same population. In the USA, Newacheck et al. demonstrated
that the prevalence of childhood disability may range from 7.3% to 30% depending on
the definition of disability used [49]. Thus, it is important for researchers to use uniform
definitions for disability to allow results to be comparable and be more relevant and
informative for planning and budgeting of services.
4.2. Human Capital vs. Friction Cost
Valuing indirect costs, especially childcare time and lost productivity, has been an
issue of much debate. As they are less straightforward to measure and more complicated
to explain for decision makers, researchers have used different methods to estimate these
costs. Among 11 studies that considered indirect non-medical costs, the human capital
approach was the most common method. Although theoretically it may be superior to the
human capital approach, the friction cost method was never used in any of the reviewed
studies. This may be due to the limited use of the friction cost method in healthcare
literature and that its costs are not readily available [20]. We suggest also that the human
capital approach could be easier to present and explain to decision makers and the public.
Three studies used alternative methods. A British study used propensity score match-
ing and compensating variation method which calculates ”the amount of additional income a
family with a disabled child would require to achieve the same living standards as a similar family
without a disabled child” [53]. In a Senegalese study on effects of meningococcal meningitis,
the opportunity cost of time lost by parents’ due to their child’s illness was reported and
valued by the parents [36]. This approach was suggested by the researchers to be more
suitable to LMIC settings. A similar approach was used in China, where parents replied to
open questions such as “How much total income do you expect that all family members would
have earned in the past year if your child did not have the disease?” [37].
The use of compensating variation is promising and could provide good evidence for
evaluating the effectiveness of disability benefits in the country as it estimates the amount
needed to fill the gap in standard of living between families with/without a disabled child.
However, it can not be used to estimate societal cost as the focus here is the household.
We would still recommend the use of human capital approach as it is the most
commonly used method and would make results comparable to other studies.
4.3. Societal vs. Household vs. Health System Perspective
The perspective may be the most determinant factor in a costing study as it would
dictate what costs to include/exclude, where to collect the data from, and who is the
audience of the study. No perspective can be claimed to be superior to others, it depends
on the context. Careful analysis of the health system of the country of the study and the
target audience should lead to the selection of the most suitable perspective.
In EU countries, disabled children can receive good quality of public healthcare,
special education, and social services at no or very minimal costs. This explains why most
studies in EU countries focus on the social perspective as most of the disability burden
falls on public services. In this context, the household perspective would underestimate
the negative effects of disability because a considerable part of the burden is shifted from
the family to the social welfare network.
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The healthcare system in the USA differs from that in Europe as there is no single
national or social health insurance in the USA. Disabled children can receive healthcare
through Medicaid, private insurance, or could even have no healthcare coverage at all.
Because of the variable and more complex health system in the USA, different studies adopt
different perspectives to cover all viewpoints. Three out of five American studies focused
on the health system perspective. This reflects the growing concern by the healthcare
payers (public or private) about the rising healthcare costs in the USA.
In developing countries, public services are of lower quality and limited coverage
leading to higher reliance on private providers. This leads to significant OOP costs for the
families. This explains why four out of five studies from developing countries focused on
the household perspective while it was used in only one out of 15 studies in developed
countries. Limited expertise in costing in developing countries, poor documentation, and
unavailability of sources of cost data may also be factors deterring researchers in those
countries from taking a wider perspective.
It was very difficult to aggregate the methods used into meaningful categories for
several reasons. The methods used to calculate each cost category were variable, but what
made it even more challenging is that many studies lacked the level of detail needed for
such analysis. We have included in Appendix F some more details from the studies on
their methods.
4.4. Developed vs. Developing
Studies originating from developing countries were fewer in number and were gen-
erally of lower quality compared to studies from developed countries. Out of 34 studies
included in full-text critical appraisal, eight were from developing countries, and only two
had low risk of bias. Studies from developing countries focused more on the household and
OOP expenses. The health system perspective was never used in studies from developing
countries. This may indicate lack of interest from decision makers in this kind of studies
and may also indicate the difficulty in collection of health system costs in these sittings.
Methods in studies from developing countries were less explicit especially in describ-
ing sources of each cost component and how it was calculated. Costs were generally lower
in developing countries, annual costs ranged ≈$500–7500 while in developed countries
they were ≈$2600–69,000. This may be partly because the cost of healthcare is lower in
these countries and partly due to methodological differences (e.g., fewer costs included).
The estimation of lifetime societal costs of CP in two studies, one in China
(≈$91,000) [42] and another in Denmark (≈$1.2–1.3 million) [40], shows a huge differ-
ence. Although both studies used the same perspective, the Danish study relied on national
register data (including all patients registered since the 1960s) and was very explicit on
details of costs included, sources of costs, and how they were calculated. The Chinese
study was based on interviews with 319 parents of CP children to ask about utilization and
expenditure related to their child disability as well as productivity loss. Less details were
offered in the Chinese study on how each cost component was calculated. This may partly
explain why both studies came to very different numbers that cannot simply be attributed
to differences in healthcare costs or wage rates.
This shows that the choice of the most suitable method may vary between countries as
it should account for differences in health systems (what services are covered by insurance
or public services and what services are paid by the families), and should also account for
the availability of data and their quality. The lack of availability of reliable population-level
cost data in developing countries makes the results of the studies less accurate and less
generalizable. This highlights the need for guidelines that set standards for conducting
and reporting cost studies which allows them to be compared across time and countries.
The guideline should be comprehensive yet flexible to be adapted to context and setting. A
notable effort in this field was undertaken by the Global Health Cost Consortium (GHCC)
in the Reference Case for Estimating the Costs of Global Health Services and Interventions
that “adopts a “comply or justify” approach, which allows the analyst to adapt to the specific
Int. J. Environ. Res. Public Health 2021, 18, 3531 13 of 25
requirements of the costing exercise, but introduces the condition that judgments about methods
choices are made explicitly and transparently” [21].
4.5. Mean vs. Median
Cost data in healthcare are typically positively skewed (right tailed). This is because a
few patients (very severe or complicated cases) use significantly more resources than the
rest which increases the mean cost. Therefore, the median is statistically more appropriate
to describe cost data and non-parametric techniques are more appropriate for analysis.
Nevertheless, decision makers are interested in average (mean) cost not the median [29]
because average cost is what they would use in budgeting. Different statistical techniques
have been used for presenting the cost results in mean costs including bootstrapping and
using the gamma distribution [29,54].
Most reviewed studies reported the mean cost. One study reported both mean and
median cost, [45] allowing readers interested in the expected cost for an individual patient
to know the median while presenting the mean for decision makers who are more interested
in average cost for the population. In this review, we assumed that mean costs are more
relevant in describing the burden on the health system and society. Thus, the mean costs
were reported in this review whenever available.
We recommend that the ideal practice would be reporting both mean and median
costs. If the mean is used, care should be taken to use the appropriate statistical techniques
to allow performing parametric analysis on cost data.
4.6. How Significant Is the Burden?
Comparing costs to CHE and GDP was used to show the extent of the burden. Taking
the UK as an example; the amount of extra costs that a family of a disabled child bear
annually (≈$2600–4200) [33] is comparable to the CHE per capita (61–98%). From the
societal perspective, the annual costs of one disability case (ASD) [38] is equal to the
country’s GDP per capita. In other words, the society loses one GDP per capita annually
for each disabled child. A similar conclusion can be reached if we compare the annual
societal costs to the GDP per capita in the Netherlands [50] (108%), Canada [47] (129%), and
Sweden [44] (130%). In the Netherlands, Hoving et al. estimated that the annual societal
costs of one CP child is 11 times CHE per capita [50].
A significant proportion of this burden falls on the families, even in countries with
very good public services. In Canada, Genereaux et al. estimated that even with widely
available public healthcare and social services, the governmental benefits compensated for
less than 6% of OOP expenses that the family of a disabled child face [47].
In developing countries, the burden is even heavier and a significant proportion of it
falls on the families. In Mexico, the OOP expenditures incurred by the disabled (DS) child’s
family is equal to the county’s CHE per capita [48]. In China, the household expenses
were found to be two to eight times the CHE per capita (for mental disability and autism
respectively) [52], while according to another study, ASD costs could be up to 17 times CHE
per capita (75% of the GDP per capita) [37]. This considerable burden on the households
explains why many families fall into poverty and incur catastrophic health expenditures as
a result of having a disabled child. This shows how significant the burden of childhood
disability but also hints at the potential savings from prevention programs.
4.7. Strengths and Limitations
This study is the first to analyse in detail the methods of estimating childhood disability
costs differentiating between methods according to perspective, time horizon, type of
disability, and country income level.
This review however had some limitations. The heterogeneity of methods did not
allow costs to be summarized and compared statistically in a meta-analysis. Time constrains
lead to limiting database searches to only four databases. As only one researcher was
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performing the review, it was not possible to have two independent researchers to select
studies according to inclusion criteria.
Search terms used to search the term “disability” included some general synonyms of
the term “disability” and terms for some specific medical conditions. However, the terms
used for specific medical condition was not a comprehensive list. It only included some of
the most common childhood conditions causing disability, while some other conditions
(e.g., hearing-impairment and visual-impairment) were not included.
Only five studies from developing countries were included in this review. This
was due to the limited number of available studies and their lower quality. Only two
studies from developing countries had a low risk of bias according to our critical appraisal.
However, a further three studies, who had moderate risk of bias, were included in our
review to allow comparison between developed and developing countries.
4.8. Recommendations for Policy Makers
Policy makers should look at childhood disability from a wider perspective and
consider the effects beyond the health system to appreciate the full picture and avoid
underestimation of the economic burden. This is important when making investment
decisions and weighing costs and benefits.
Governments should be encouraged to finance programs that are proven effective
in preventing avoidable disabilities. Providing facilities and personnel to ensure safer
deliveries, especially in rural areas, can significantly decrease the number of CP cases
caused by antenatal complications. A facility/program for safe delivery in a developing
country can prevent hundreds of traumatic CP cases and save considerable potential
lifelong costs of their disability. Some medications to prevent premature delivery are also
promising in reducing CP because of prematurity. Amniocentesis for detection of DS and
counselling for positive mothers should be provided by public facilities. Early diagnosis,
rehabilitation, special education programs, and inclusion in the labor market are effective
in improving the outcome of ASD cases. Investing in these interventions with the target of
making autistic children more independent and to qualify them to enter the labor market
will significantly reduce the lifetime costs of their disability. The same can be concluded for
interventions, equipment, and programs to help children with hearing, visual, or physical
impairment to overcome their disability and reduce the burden on their family and society.
The cost of providing cochlear implants for hearing-impaired children at a young age to
make them pursue almost normal academic achievement cannot be compared to the cost
of living with lifelong permanent hearing impairment if the operation is delayed. Cochlear
implantation is a relatively expensive operation, but the annual loss of one GDP per capita
is much more costly to society. This is the argument that should be presented to policy
makers to persuade them to take a more societal and long-term viewpoint when making a
decision to pay for an immunization program, rehabilitation facility, safe labor initiative or
subsidising prosthetics.
Policies in developing countries should aim—beside prevention programs—to reduce
the economic burden on the families by providing/subsidising services that the families
must pay OOP. Special subsidised insurance schemes and arrangements can be made to
allow the children to receive services from private providers if they are not available in
public facilities.
Donor organizations should be aware of the magnitude of the economic burden and
the potential for preventing it. They should be encouraged to fund programs and services
that reduce the OOP expenses by the households to prevent catastrophic expenditure.
Legislation should be passed to encourage employers to allow more disabled persons
to enter the labor market.
Int. J. Environ. Res. Public Health 2021, 18, 3531 15 of 25
4.9. Need for Further Research
More research is needed on the cost-effectiveness of interventions and prevention pro-
grams for childhood disabilities especially in developing countries. The cost of illness stud-
ies like those included in this review can be used as inputs in such cost-effectiveness studies.
More cost of disability studies in developing countries are needed. These studies
need to include more details on how costs are calculated and become more explicit in their
methodology. A societal perspective should be adopted to show the extent of the burden
beyond the family and the health system.
Studies to establish the relation between poverty and disability in developing countries
are also needed.
5. Conclusions
All reviewed studies on the cost of childhood disability—despite their methodological
heterogeneity—have reached the conclusion that childhood disability causes a considerable
burden on family, health system, and society. Childhood disability could be costing societies
up to one GDP per capita annually for each disabled child.
This study could not combine the estimated costs into one measure because the studies
were not uniform in the costs they included, sources of costs, and methods of calculation.
In addition, perspective, study setting, time horizon, and type of disability are all variables
that affect which costs are included and how they are calculated. However, standardizing
the way we evaluated these costs in relation to the country’s CHE and GDP allowed us to
display the results in a graphical way to allow better understanding of the global picture of
the burden of childhood disability. Societies in developed countries pay high costs because
of childhood disabilities, and families in developing countries are forced below the poverty
line by spending most of their income on their disabled child.
Policy makers should be made aware of the heavy consequences of childhood disabil-
ity, and search for efficient ways to mitigate these effects. Interventions that have already
proven effective in preventing disability should be adopted to prevent the occurrence of
disability altogether. For non-preventable disabilities; policy makers must ensure the pro-
vision of healthcare, special education, and social services for disabled children and their
families to alleviate some of the burden on them and allow them to enter the workforce and
be more productive. Providing these services, besides being a moral and ethical obligation
on more-abled members of society, is reflected positively in the economy by decreasing the
societal costs of disabled children and increasing their household productivity.
Research from developing countries is low in quantity and quality. Researchers in
developing countries are required to produce more evidence and be clear on details of
methods used and how costs were calculated. Careful analysis of the context and the
health system of the study setting is essential to reach the correct decisions regarding the
perspective of the study and what costs to include. Economic evaluation of prevention pro-
grams and therapeutic interventions is needed to highlight potential savings by preventing
childhood disabilities or modifying their effect.
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Appendix A. Search Strategy for OVID Medline Database
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process and Other Non-Indexed
Citations, Daily and Versions(R) <1946 to 03 July 2019>
1. (cost* adj5 (economic or illness or sickness or disease* or care or direct or indirect)).mp.
[mp=title, abstract, original title, name of substance word, subject heading word,
floating sub-heading word, keyword heading word, organism supplementary concept
word, protocol supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms] (127447)
2. exp “cost of illness”/ or exp healthcare costs/ (82347)
3. 1 or 2 (146362)
4. (disable* or disabilit* handicap* or impairment* paralys* paralyz*).mp. [mp=title,
abstract, original title, nameof substance word, subject heading word, floating sub-
heading word, keyword heading word, organism supplementary concept word,
protocol supplementary concept word, rare disease supplementary concept word,
unique identifier, synonyms] (77792)
5. exp Disabled Persons/ (62208)
6. cerebral palsy.mp. [mp=title, abstract, original title, name of substance word, sub-
ject heading word, floating sub-heading word, keyword heading word, organism
supplementary concept word, protocol supplementary concept word, rare disease
supplementary concept word, unique identifier, synonyms] (26008)
7. exp cerebral palsy/ (19602)
8. (down* syndrome or mongolism or trisomy?21).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, floating sub-heading word, keyword
heading word, organism supplementary concept word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier, synonyms] (29343)
9. exp down syndrome/ (23636)
10. autis*.mp. [mp=title, abstract, original title, name of substance word, subject heading
word, floating sub-heading word, keyword heading word, organism supplementary
concept word, protocol supplementary concept word, rare disease supplementary
concept word, unique identifier, synonyms] (46566)
11. exp Autistic Disorder/ or exp Autism Spectrum Disorder/ (26617)
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (187674)
13. (child* or boy* or girl* or adolescent* or infant* or pediatric* or paediatric or (schoolage*
or (school adj1 age*)) or (preschool* or (pre adj1 school*))).mp. [mp=title, abstract,
original title, name of substance word, subject heading word, floating sub-heading
word, keyword heading word, organism supplementary concept word, protocol
supplementary concept word, rare disease supplementary concept word, unique
identifier, synonyms] (3934927)
14. exp child/ or exp Disabled Children/ or exp Child Health Services/ (1841396)
15. 13 or 14 (3935165)
16. 3 and 12 and 15 (1121)
17. limit 16 to (english language and yr=“1980 -Current”) (1046)
Appendix B. Search Strategy for OVID Embase Database
Embase Classic+Embase <1947 to 2019 July 03>
1. (cost* adj5 (economic or illness or sickness or disease* or care or direct or indirect)).mp.
[mp=title, abstract, heading word, drug trade name, original title, device manufac-
turer, drug manufacturer, device trade name, keyword, floating subheading word,
candidate term word] (284046)
2. exp “cost of illness”/ or exp health care costs/ (291451)
3. 1 or 2 (370332)
4. (disable* or disabilit* handicap* or impairment* paralys* paralyz*).mp. [mp=title,
abstract, heading word, drug trade name, original title, device manufacturer, drug
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manufacturer, device trade name, keyword, floating subheading word, candidate
term word] (63633)
5. exp Disabled Persons/ (57465)
6. cerebral palsy.mp. [mp=title, abstract, heading word, drug trade name, original
title, device manufacturer, drug manufacturer, device trade name, keyword, floating
subheading word, candidate term word] (41772)
7. exp cerebral palsy/ (38329)
8. (down* syndrome or mongolism or trisomy?21).mp. [mp=title, abstract, heading
word, drug trade name, original title, device manufacturer, drug manufacturer, device
trade name, keyword, floating subheading word, candidate term word] (40125)
9. exp down syndrome/ (36240)
10. autis*.mp. [mp=title, abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword, floating subheading
word, candidate term word] (69358)
11. exp Autistic Disorder/ or exp Autism Spectrum Disorder/ (63878)
12. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (230190)
13. (child* or boy* or girl* or adolescent* or infant* or pediatric* or paediatric or (schoolage*
or (school adj1 age*)) or (preschool* or (pre adj1 school*))).mp. [mp=title, abstract,
heading word, drug trade name, original title, device manufacturer, drug manu-
facturer, device trade name, keyword, floating subheading word, candidate term
word] (4146231)
14. exp child/ or exp Disabled Children/ or exp Child Health Services/ (2909761)
15. 13 or 14 (4427076)
16. 3 and 12 and 15 (1415)
17. limit 16 to (english language and yr=“1980-Current”) (1326)
Appendix C. Search Strategy for OVID Econlit Database
Econlit <1886 to June 27, 2019>
1. (disable* or disabilit* handicap* or impairment* paralys* paralyz*).mp. [mp=heading
words, abstract, title, country as subject] (1187)
2. cerebral palsy.mp. [mp=heading words, abstract, title, country as subject] (9)
3. (down* syndrome or mongolism or trisomy?21).mp. [mp=heading words, abstract,
title, country as subject] (10)
4. autis*.mp. [mp=heading words, abstract, title, country as subject] (70)
5. (child* or boy* or girl* or adolescent* or infant* or pediatric* or paediatric or (schoolage*
or (school adj1 age*)) or (preschool* or (pre adj1 school*))).mp. [mp=heading words,
abstract, title, country as subject] (39334)
6. (cost* or burden*).mp. [mp=heading words, abstract, title, country as subject] (191228)
7. 1 or 2 or 3 or 4 (1268)
8. 5 and 6 and 7 (44)
9. limit 8 to (yr=“1980-Current” and english) (42)
Appendix D. Search Strategy for OVID Global Health Database
Global Health <1910 to 2019 Week 26>
1. (cost* adj5 (economic or illness or sickness or disease* or care or direct or indi-
rect)).mp. [mp=abstract, title, original title, broad terms, heading words, identifiers,
cabicodes] (24319)
2. exp “cost of illness”/ or exp health care costs/ (11630)
3. estimated costs/ or health care costs/ or costs/ or social costs/ or unit costs/ or
specific costs/ or total costs/ (26116)
4. exp “cost analysis”/ or exp costs/ or exp “cost effectiveness analysis”/ (30831)
5. 1 or 2 or 3 or 4 (38096)
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6. (disable* or disabilit* handicap* or impairment* paralys* paralyz*).mp. [mp=abstract,
title, original title, broad terms, heading words, identifiers, cabicodes] (6019)
7. exp Disabled Persons/ (4887)
8. cerebral palsy.mp. [mp=abstract, title, original title, broad terms, heading words,
identifiers, cabicodes] (1407)
9. exp cerebral palsy/ (1061)
10. (down* syndrome or mongolism or trisomy?21).mp. [mp=abstract, title, original title,
broad terms, heading words, identifiers, cabicodes] (1981)
11. autis*.mp. [mp=abstract, title, original title, broad terms, heading words, identifiers,
cabicodes] (2467)
12. disabilities.sh. (7353)
13. exp disabilities/ or exp people with disabilities/ (11117)
14. cerebral palsy.sh. (1061)
15. exp autism/ (1831)
16. Down’s syndrome.sh. (1623)
17. 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 (18089)
18. (child* or boy* or girl* or adolescent* or infant* or pediatric* or paediatric or (schoolage*
or (school adj1 age*)) or (preschool* or (pre adj1 school*))).mp. [mp=abstract, title,
original title, broad terms, heading words, identifiers, cabicodes] (530913)
19. exp children/ (339666)
20. 18 or 19 (530913)
21. 5 and 17 and 20 (108)
22. limit 21 to (english language and yr=“1980-Current”) (89)
Appendix E
Table A1. Checklist Used for Critical Appraisal.
Yes No N/A
Was a well-defined question posed in answerable form?
1. Did the study examine costs of the service(s) or programme(s)?
2. Did the study involve a comparison group?
3. Was a viewpoint for the analysis stated and was the study placed in any particular decision-making context?
4. Were the patient population and any relevant subgroups adequately defined?
Were all the important and relevant costs identified?
5. Was the range wide enough for the research question at hand?
6. Did it cover all relevant viewpoints? (Possible viewpoints include the community or social viewpoint, and those of
patients and third-party payers. Other viewpoints may also be relevant depending upon the particular analysis.)
7. Were the capital costs, as well as operating costs, included?
Were costs measured accurately in appropriate physical units (e.g., hours of nursing time, number of physician visits, lost work-days)?
8. Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the
subsequent analysis?
9. Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these
circumstances handled appropriately?
Were the costs valued credibly?
10. Were the sources of all values clearly identified? (Possible sources include market values, patient or client
preferences and views, policy-makers’ views and health professionals’ judgements)?
11. Were market values employed for changes involving resources gained or depleted?
12. Where market values were absent (e.g., volunteer labour), or market values did not reflect actual values (such as
clinic space donated at a reduced rate), were adjustments made to approximate market values?
Were costs adjusted for differential timing?
13. Were costs that occur in the future ‘discounted’ to their present values?
14. Was there any justification given for the discount rate used?
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Table A1. Cont.
Yes No N/A
Was uncertainty in the estimates of costs adequately characterized?
15. If patient-level data on costs available, were appropriate statistical analyses performed?
16. Were the conclusions of the study sensitive to the uncertainty in the results, as quantified by the statistical analysis?
17. Was heterogeneity of the patient population recognized, for example by presenting study results for relevant
subgroups?
Did the presentation and discussion of study results include all issues of concern to users?
18. Were the results compared with those of others who have investigated the same question? If so, were allowances
made for potential differences in study methodology?
19. Did the study discuss the generalisability of the results to other settings and patient/client groups?
20. Were the implications of uncertainty for decision-making, including the need for future research, explored?
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employment because of their
child’s condition using a
human capital
approachbased on the
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Claim database was used to
conduct retrospective
cohort study
OOP expenses: from claims
data (co-pay and
co-insurance)
The observation period for
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cost of CP in South
Korea was
≈$32,000, which is
1.8 times the basic
lifetime medical








































Total costs: multiply each
resource used by unit costs
















































Costs were calculated by
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annual multiple Not clear
Formula: the raising burden
of children with disability =
[(the income per person per
year of family of normal
children—that of family of
disabled children) + (the cost




























ASD in a local
hospital
A questionnaire with open
questions:
(How much total income do
you expect that all family
members would have
earned in the past year if
your child did not have the
disease?)
(What were the total
educational expenses of the
ASD or OD child in your
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